Placebo News and Research

RSS

Lund University professor to coordinate oral insulin study for type 1 diabetes

Type 1 diabetes is the autoimmune form of diabetes, in which the patients' insulin-producing beta cells are destroyed by their own immune system. "We know that if a person has two autoantibodies and one of them is against insulin, there is a 50 per cent risk that they will develop type 1 diabetes within five years. It doesn't matter how old you are", says Ake Lernmark, Professor of Experimental Diabetes Research at Lund University in Sweden.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Alendronate decreases BMD loss in prostate cancer

Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.

19 Sep 2012

Inhaled pain relief effective in first labor stage

A Cochrane review shows that inhaled pain relief is more effective than no pain relief at all in reducing pain intensity during the first stage of labor, say researchers.

19 Sep 2012

Tranexamic acid lifesaving across the board

Tranexamic acid confers survival benefits in trauma patients irrespective of their baseline mortality risk, shows a prespecified analysis of CRASH-2.

18 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.

17 Sep 2012

Placebo News and Research

Lund University professor to coordinate oral insulin study for type 1 diabetes

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Alendronate decreases BMD loss in prostate cancer

Inhaled pain relief effective in first labor stage

Tranexamic acid lifesaving across the board

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Antimuscarinics only moderately effective for overactive bladder

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Insufficient evidence to support effectiveness of black cohosh for menopausal symptoms

Montelukast possible surgery alternative for obstructive sleep apnea

Addition of sorafenib to chemotherapy does not prolong survival

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News